Hot Investor Mandate: Life Sciences Advisory & VC Firm Seeks Life Sciences Companies Targeting Oncology, CNS, Infectious Diseases, and More

10 Mar

A global life sciences advisory and venture capital firm provides strategic advisory services alongside direct venture investments in biotechnology, pharmaceutical, medical device, and digital health companies. The firm maintains an international investment portfolio spanning multiple healthcare sectors and collaborates with companies and institutions across North America, Europe, and other global markets. In addition to capital, the firm supports portfolio companies through strategic guidance in product development, regulatory planning, and commercialization strategy.  

The firm invests across therapeutics, medical technologies, diagnostics, digital health, and platform-based innovations that address major unmet clinical needs. Areas of activity include oncology, infectious diseases, neurology, immunology, women’s health, and device-enabled interventions, as well as computational and data-driven healthcare approaches. The firm prioritizes opportunities with strong scientific rationale, translational potential, and clear regulatory and commercial pathways.  

From a company and management team perspective, the firm partners with teams demonstrating scientific credibility, disciplined development planning, and operational capability to advance programs efficiently through key milestones. The firm values strong intellectual property positions, robust preclinical or clinical data packages, and clearly defined global development and market entry strategies. Leveraging its combined investment and advisory capabilities, the firm supports companies through integrated guidance across R&D, regulatory strategy, clinical development, business development, and commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Europe 2026 IPC Finalists 

10 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the finalists for the Innovator’s Pitch Challenge (IPC) at RESI Europe 2026, taking place in Lisbon during the week of March 23. The event will bring together early-stage life science and healthcare innovators with a global community of investors seeking opportunities across drugs, devices, diagnostics, and digital health (4Ds).

This year’s IPC will feature over 20 presenting companies, with finalists pitching their technologies in dedicated sessions throughout the conference. These startups represent a diverse range of innovations aimed at solving critical healthcare challenges and advancing the next generation of life science breakthroughs.

The IPC gives founders the opportunity to pitch directly to active investors, including venture capital firms, family offices, corporate venture groups, and angel investors. Presenting companies receive valuable feedback from investor judges while gaining visibility among the investors and strategic partners attending RESI Europe.

Finalists will also have opportunities to connect with investors through RESI’s partnering system, as well as continue conversations during networking sessions and throughout the conference.

About the RESI Innovator’s Pitch Challenge

The IPC is a cornerstone of the RESI conference series. Each pitch session brings together a coordinated panel of investors who provide interactive feedback and questions designed to help founders refine their fundraising strategy and investment narrative.

Companies selected as IPC finalists receive RESI conference registration, the opportunity to present live to investors, and the chance to build relationships with members of the RESI investment community.

Join Us at RESI Europe 2026

RESI Europe 2026 will bring together founders, investors, and strategic partners for a full day of programming including investor panels, workshops from sponsors, networking opportunities, and the Innovator’s Pitch Challenge.

Attendees will have the opportunity to engage with the early-stage life science ecosystem through structured partnering meetings and educational sessions focused on fundraising and company development.

Register for RESI Europe

Meet the RESI Europe 2026 Innovator’s Pitch Challenge Finalists:

Applications Now Open for RESI San Diego

The Innovator’s Pitch Challenge at RESI San Diego offers life science startups the opportunity to present directly to a curated panel of active investors and receive real-time, constructive feedback. Each pitch includes a live Q&A with investor judges and extended exposure through participation in the IPC exhibition hall.

Apply to Pitch at RESI San Diego

 

Tags: , , , , , , , , , , , ,

Fundraising Bootcamp Ahead of RESI Europe 2026: Preparing Founders for Investor Engagement 

10 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation (LSN), in collaboration with Cuatrecasas, will host an exclusive Fundraising Bootcamp in Lisbon ahead of RESI Europe 2026, offering early-stage life science and healthcare executives a focused opportunity to refine their fundraising strategy and strengthen investor engagement skills. 

Taking place the day before the conference, the bootcamp will bring together founders, investors, and industry experts for an interactive session designed to help companies better position themselves for capital and partnerships within the global life science ecosystem. 

Event Details 

Date and Time: Sunday, March 22, 2026 | 2:00 PM – 5:30 PM
Location: Cuatrecasas Law Firm
Av. Fontes Pereira de Melo 6
1050-121 Lisboa, Portugal
Cost: Free to attend (registration required) 

This workshop will focus on practical, real-world fundraising insights that early-stage companies can immediately apply when engaging with investors at RESI Europe and beyond. Participants will hear directly from experienced professionals who work with startups and investors across the life science sector. 

Agenda Highlights 

Signal, Legibility, and Risk Mitigation in Global Fundraising 
Learn how investors interpret signals when evaluating early-stage companies and how founders can structure their development plans to become more “legible to capital.” The discussion will also explore strategies for mitigating risk in global fundraising environments. 

Shark Tank Session (Company Pitch) 
Selected companies will have the opportunity to present their pitch and receive direct feedback from experienced investors and industry professionals in an interactive format designed to sharpen messaging and highlight areas for improvement. 

Networking 
The bootcamp will conclude with time for founders and participants to connect with fellow entrepreneurs, investors, and industry experts before the start of RESI Europe. 

This pre-conference session provides a valuable opportunity for innovators preparing for RESI Europe to strengthen their fundraising approach, refine their investor messaging, and begin building connections within the RESI community. 

Space is limited, and applications will be accepted in the order they are received. 

Life Science Nation looks forward to welcoming founders and investors to Lisbon for this interactive fundraising session ahead of RESI Europe 2026. 

Sign up for Bootcamp

Tags: , , , , , , , , , ,

RESI San Diego 2026: Investor Panel Lineup Announced 

10 Mar

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Life Science Nation (LSN) has announced the investor panel lineup for RESI San Diego 2026, taking place June 22 at the JULEP Venue in San Diego during Convention Week, followed by four days of virtual partnering on June 23–24 and June 29–30. The hybrid format combines in-person networking with extended virtual partnering, giving founders and investors additional opportunities to continue conversations and schedule meetings beyond the live event.

Investor panels are a cornerstone of the RESI conference series, bringing together active investors and strategic partners to share perspectives on the evolving life science funding environment. These sessions offer founders and executives the opportunity to hear directly from investors about how they evaluate opportunities across drugs, devices, diagnostics, and digital health.

This year’s discussions will explore several key themes shaping early-stage investment. Topics will include how emerging companies can successfully engage pharmaceutical partners, what strategic investors and corporate venture capital groups are prioritizing in today’s market, and how medtech innovators can position themselves to attract both financial and strategic partners. Panels will also examine investment trends in diagnostics and oncology, the growing role of artificial intelligence in healthcare innovation, and the challenges many startups face when moving from seed capital to institutional venture funding.

RESI San Diego 2026 Investor Panels

Time  Panel Title 
9AM  Inside Pharma Partnering 
How Early-Stage Companies Can Engage Pharma 
10AM  Strategic Partnerships in Medtech 
What the Next Generation of Device Companies Must Deliver 
11AM  Strategic Capital: The Role of CVCs 
Investing Where Innovation Meets Industry
1PM  New Frontiers in Diagnostics 
Investing in Technologies Enabling Earlier Disease Detection 
2PM  Emerging Approaches in Cancer Therapies 
How New Modalities Are Standing Out in a Competitive Market 
3PM  AI at the Frontlines of Healthcare Innovation 
Building Scalable Companies at the Intersection of Data and Medicine 
4PM  Crossing the Venture Gap 
Moving from Seed Funding to Venture Rounds 
Register for RESI San Diego
Apply to Speak at RESI San Diego

In addition to investor panels, RESI San Diego will feature the Innovator’s Pitch Challenge, where selected startups present their technologies directly to investor judges in an interactive pitch format. The conference also offers extensive one-on-one partnering opportunities, allowing attendees to schedule meetings with investors, strategic partners, and industry leaders through the RESI partnering system.

Held during San Diego’s broader biotech Convention Week, RESI San Diego provides a focused environment for early-stage companies to connect with active healthcare investors and strategic partners. The event brings together venture capital firms, family offices, corporate venture groups, and industry leaders seeking opportunities across drugs, devices, diagnostics, and digital health.

Register today to secure your place at RESI San Diego 2026 and connect with investors shaping the future of healthcare innovation. Super Early Bird rates are available through April 17.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , ,

The Trap of Complacency 

10 Mar

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

One message we consistently emphasize when speaking with early-stage companies is the importance of looking beyond your local ecosystem and building relationships with investors globally. Too often, founders assume they have plenty of time to expand their network, particularly in regions that offer strong support for launching startups. 

Paradoxically, those supportive ecosystems can create a false sense of security. Grants, incubators, and local funding programs can make it feel as though capital will always be available. In reality, many regions simply do not have enough follow-on capital to support every company that begins there. When the initial funding runs out, startups may suddenly find themselves approaching a financial cliff. At that point, companies that haven’t built relationships outside their region may be forced to accept unfavorable investment terms just to survive. 

Another common misconception is that companies should only begin speaking with investors once they are actively fundraising. In practice, this approach often backfires. Founders tend to underestimate how long fundraising actually takes—a typical fundraising process can last anywhere from 9 to 18 months. Waiting until the last moment leaves little room to build relationships or refine the company’s strategy. 

Early conversations with investors can be extremely valuable even when a company is not raising capital. Investors bring deep industry knowledge and experience, and their feedback can help companies sharpen their development plans, prioritize critical data, and better understand what will make them investable. Just as importantly, fundraising is ultimately driven by relationships. Building those relationships early can significantly accelerate the process when the time comes to raise capital. 

Rather than treating fundraising as something that switches on and off, companies should think of it more like a dial—one that adjusts the intensity of their efforts over time. Engaging with investors early should be considered just as essential as customer discovery or market research. These conversations can help gauge investor interest, identify potential weaknesses in a strategy, and prevent companies from investing significant time and resources in a direction that may not resonate with the market. 

Sometimes, this early feedback leads to a pivot that ultimately strengthens the company. Making adjustments sooner rather than later can help a startup reach the market faster—or even transform a company that might otherwise fail into one that achieves a successful exit. 

Register for RESI Europe

Tags: , , , , , , ,

Hot Investor Mandate: Family-Office Backed Investment Vehicle Seeks Innovative Medtech Opportunities in US, Western Europe, and Asia

10 Mar

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Investment Arm of Large Healthcare Enterprise Invests and Partners With Innovations With China and Global Market Potential

10 Mar

The firm is the investment arm of a diversified healthcare enterprise headquartered in Asia with international operations. The broader organization operates across medical innovation incubation, manufacturing, and large-scale commercialization, with a strong focus on technology-driven healthcare solutions and intellectual property development. Through its investment activities, the firm supports innovative healthcare companies by providing capital as well as access to industrial capabilities and commercialization infrastructure. The broader organization maintains a large healthcare distribution platform serving hospitals and pharmacies nationwide, enabling portfolio companies to access substantial market channels. The firm evaluates global investment opportunities with strong potential for commercialization in the China market.  

The firm focuses on life sciences and healthcare opportunities spanning therapeutics, diagnostics, medical devices, R&D tools, and AI-enabled healthcare platforms. Areas of particular interest include oncology and immuno-oncology, advanced therapeutic modalities such as cell and gene therapy, and innovative medical technologies with clear clinical application. Through its technology innovation initiatives, the organization collaborates with research institutions to identify and develop original scientific breakthroughs, including first-in-class medicines and novel medical devices. While the firm frequently evaluates later-stage assets and partnership opportunities, it also considers early-stage technologies with strong scientific differentiation and long-term commercial potential.  

From a company and partnership perspective, the firm prioritizes opportunities with meaningful relevance to the China healthcare market and the ability to leverage the organization’s regulatory, manufacturing, and commercial infrastructure. The firm looks for strong scientific foundations, clear unmet clinical needs, differentiated product positioning, and credible strategies for market entry and expansion. Portfolio companies may benefit from support across R&D collaboration, industrial incubation, regulatory strategy, manufacturing scale-up, and nationwide commercialization. The firm maintains a flexible investment approach and may participate as either a lead investor or a co-investor depending on the opportunity and partnership structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

← Older Entries